An observational study in Ovarian Cancer, sponsored by Tishreen University. Completed at 1 site in Syrian Arab Republic. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-15.
Sponsored by Tishreen University · Observational
the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer.
Ovarian cancer (OC) is the eighth most common cause of death worldwide, and current studies show that the death numbers caused by it will rise dramatically in the coming years. As the epidemiological features of the cancer may vary, studying these different characteristics can help us improve treatment outcomes and add preventive measures. In addition, giving special attention to these features in developing countries, or countries undergoing crisis, will help us understand the associated risk factors in these regions.
3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
This study's enrollment of 531 is above the median of 200 across 616 observational studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Tishreen University is the lead sponsor of 15 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
all women with ovarian cancer, with age ≥18 years,who have primary ovarian malignancy and underwent surgical or non-surgical treatment.
the data recorded from records of the Departments of Gynecology and Oncology at Tishreen University Hospital in Latakia, Al-Bairouni University Hospital in Damascus, and Ibn Rushd Hospital in Aleppo, which are the 3 major hospitals in Syria that admit and treat patients with ovarian cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all ovarian cancer patients that meet the criteria of the study
age
the age of patients at the time of diagnosis
Time frame: jan 2017 - july 2021
ovarian cancer grade
ovarian cancer grades frequency among patients
Time frame: jan 2017 - july 2021
histological type of ovarian cancer
detect the most common type of ovarian cancer
Time frame: jan 2017 - july 2021
sideness of ovarian cancer
study the frequency of bilateral or unilateral ovarian cancer
Time frame: jan 2017 - july 2021
Cancer Antigen-125
Cancer Antigen-125 levels, if they are normal or high in ovarian cancer.
Time frame: jan 2017 - july 2021
Treatment
detect if the patient underwent surgery or chemotherapy or the both
Time frame: jan 2017 - july 2021
symptoms of ovarian cancer
detect symptoms of disease at diagnosis time
Time frame: jan 2017 - july 2021
Plan to share: Undecided — data can be shared upon your request
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tishreen University